A5052336062- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- Cancer therapeutics and mechanisms
- Cancer Immunotherapy and Biomarkers
- Gastric Cancer Management and Outcomes
- RNA modifications and cancer
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Peptidase Inhibition and Analysis
- Radiomics and Machine Learning in Medical Imaging
- Cancer Treatment and Pharmacology
- Neuroendocrine Tumor Research Advances
- Cancer, Hypoxia, and Metabolism
- Acute Lymphoblastic Leukemia research
- Cancer-related Molecular Pathways
- Cancer Research and Treatments
- Pancreatic and Hepatic Oncology Research
- Head and Neck Cancer Studies
- Medical Imaging Techniques and Applications
- PI3K/AKT/mTOR signaling in cancer
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
Brown University
2019-2025
Lifespan
2020-2025
Providence College
2020-2025
Massachusetts General Hospital
2013-2024
Rhode Island Hospital
2020-2024
Harvard University
2014-2021
Memorial Sloan Kettering Cancer Center
2007-2017
American Society of Clinical Oncology
2003-2017
NYU Langone Health
2017
Syracuse University
2017
PD-1 inhibitors are established agents in the management of non-small cell lung cancer (NSCLC); however, only a subset patients derives clinical benefit. To determine activity PD-1/PD-L1 within clinically relevant molecular subgroups, we retrospectively evaluated response patterns among EGFR-mutant, anaplastic lymphoma kinase (ALK)-positive, and EGFR wild-type/ALK-negative patients.We identified 58 treated with inhibitors. Objective rates (ORR) were assessed using RECIST v1.1. PD-L1...
The purpose of this article is to provide updated recommendations for the treatment patients with stage IV non-small-cell lung cancer. A literature search identified relevant randomized trials published since 2002. scope guideline was narrowed chemotherapy and biologic therapy. An Update Committee reviewed made recommendations. One hundred sixty-two publications met inclusion criteria. Recommendations were based on strategies that improve overall survival. Treatments only progression-free...
Purpose To provide evidence-based recommendations to update the American Society of Clinical Oncology guideline on systemic therapy for stage IV non–small-cell lung cancer (NSCLC). Methods An Update Committee NSCLC Expert Panel based a systematic review randomized controlled trials from January 2007 February 2014. Results This reflects changes in evidence since previous guideline. Recommendations There is no cure patients with NSCLC. For performance status (PS) 0 1 (and appropriate patient...
Gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, induces radiographic regressions and symptomatic improvement in patients with non-small-cell lung cancer (NSCLC). Phase II trials suggested female sex adenocarcinoma were associated response. We undertook this analysis to identify additional clinical pathologic features sensitivity gefitinib. reviewed medical records, material, imaging studies all 139 NSCLC treated on one three consecutive gefitinib monotherapy...
To determine the role of adjuvant chemotherapy and radiation therapy in patients with completely resected stage IA-IIIA non-small-cell lung cancer (NSCLC).The Cancer Care Ontario Program Evidence-Based American Society Clinical Oncology convened a Joint Expert Panel August 2006 to review evidence draft recommendations for these therapies.Available data support use cisplatin-based NSCLC; however, strength consequent vary by disease stage. Adjuvant appears detrimental survival stages IB II,...
Currently no objective grading system for pulmonary adenocarcinomas exists. To determine whether specific histologic patterns or combinations thereof could be linked to an system, the in metastatic tumor deposits was compared with seen corresponding 73 primary a pattern had higher propensity metastasize. The concordance of predominant and metastases 100% micropapillary, 86% solid, 42% acinar, 23% papillary types adenocarcinoma. Informed by these results, 3-tier based on subtypes established....
An American Society of Clinical Oncology (ASCO) focused update updates a single recommendation (or subset recommendations) in advance regularly scheduled guideline update. This document one the ASCO Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer (NSCLC) regarding switch maintenance chemotherapy.
Purpose Given the pivotal role of epidermal growth factor receptor (EGFR) inhibitors in advanced EGFR-mutant non–small-cell lung cancer (NSCLC), we tested adjuvant erlotinib patients with early-stage NSCLC. Materials and Methods In this open-label phase II trial, resected stage IA to IIIA (7 th edition American Joint Committee on Cancer staging system) NSCLC were treated 150 mg per day for 2 years after standard chemotherapy or without radiotherapy. The study was designed 100 powered...
Abstract Purpose: Most ALK-positive lung cancers will develop ALK-independent resistance after treatment with next-generation ALK inhibitors. MET amplification has been described in patients progressing on inhibitors, but frequency of this event not comprehensively assessed. Experimental Design: We performed FISH and/or sequencing 207 posttreatment tissue (n = 101) or plasma 106) specimens from cancer to detect genetic alterations. evaluated inhibitor sensitivity cell lines alterations and...
Basic helix-loop-helix transcription factors of the achaete-scute family are instrumental in Drosophila neurosensory development and candidate regulators mammalian central nervous system neural crest. We report isolation initial characterization a human homolog that is highly expressed two neuroendocrine cancers, medullary thyroid cancer (MTC) small cell lung (SCLC). The gene, which we have termed homology 1 (hASH1), was cloned from MTC cDNA library. It encodes predicted protein 238 aa 95%...
This phase II study was conducted to assess the efficacy of temozolomide in patients with relapsed small cell lung cancer (SCLC).Patients disease progression after one or two prior chemotherapy regimens received at 75 mg/m(2)/d for 21 days a 28-day cycle. The primary endpoint overall response rate [ORR; complete (CR) plus partial (PR)], which evaluated separately sensitive and refractory cohorts. In available tissue, we assessed O(6)-methylguanine-DNA methyltransferase (MGMT) promoter...
The American Society for Radiation Oncology (ASTRO) produced an evidence-based guideline on external-beam radiotherapy patients with locally advanced non-small-cell lung cancer (NSCLC). Because of its relevance to the Clinical (ASCO) membership, ASCO endorsed after applying a set procedures and policy that are used critically examine endorse guidelines developed by other development organizations.The ASTRO was reviewed content experts clinical accuracy methodologists developmental rigor. On...
In patients with epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma, treatment erlotinib or gefitinib is associated a 75% radiographic response rate and progression-free survival of approximately 12 months. The most common mechanism acquired resistance to development secondary mutation in EGFR, suggesting that these tumors continue depend on EGFR signaling. We hypothesized combined blockade would overcome adenocarcinoma. To evaluate the toxicity efficacy cetuximab erlotinib,...
ALK rearrangements predict for sensitivity to tyrosine kinase inhibitors (TKIs). However, responses TKIs are generally short-lived. Serial molecular analysis is an informative strategy identifying genetic mediators of resistance. Although multiple studies support the clinical benefits repeat tissue sampling, utility longitudinal circulating tumor DNA has not been established in ALK-positive lung cancer.Using a 566-gene hybrid-capture next-generation sequencing (NGS) assay, we performed...